China Pharma Update: Hospital Tender Reforms Open Doors for Foreign Pharma — Key Takeaways

As of Q1 2025, 23 provincial-level regions in China have adopted revised hospital tender (医院招标, yīyuàn zhāobiāo) evaluation criteria that reduce the weight of price from 70-80% to 45-55%, creating measurable openings for foreign pharmaceutical companies (外资药企, wàizī yàoqǐ) previously locked out by the Volume-Based Procurement (集中带量采购, jízhōng dàiliàng cǎigòu) system. This policy recalibration follows nine consecutive VBP rounds since 2018 that squeezed foreign drug margins by an average 43%, while the new framework allows quality, innovation, and real-world evidence to account for up to 40% of tender scores.

The shift signals China’s dual intent: control healthcare costs, while preserving incentives for multinational R&D investment. For foreign pharma executives re-evaluating China strategy, these tender reforms represent the most significant market-access change in half a decade. Below are the five key takeaways from this policy pivot, with data and decision context for executives.

New Tender Evaluation Criteria Favor Quality Over Price Alone

The defining change in the 2024-2025 tender reforms is the introduction of multi-dimensional scoring matrices. Under the original VBP framework, price accounted for 70-80% of the winning bid criteria, effectively eliminating most foreign drugs priced above domestic generics. The new guidelines cap price weight at 55%, while quality metrics — including bioequivalence data, manufacturing GMP certifications (Chinese GMP: 药品生产质量管理规范, yàopǐn shēngchǎn zhìliàng guǎnlǐ guīfàn), and post-market surveillance records — now constitute 20-25%. Clinical value and innovation, evaluated through real-world evidence generated in Chinese hospitals, account for the remaining 15-20%.

This recalibration directly benefits foreign pharma companies with established quality reputations and existing clinical trial data in China. In the first three tender rounds conducted under the new framework across pilot provinces, foreign-invested enterprises won 28% of awarded contracts, compared to a 12% average in the nine pure VBP rounds between 2018 and 2023. The win rate increase is most pronounced in therapeutic categories with strong differentiation — oncology biologics saw a 35% foreign-company win rate under the new criteria, versus 9% under price-only VBP.

However, executives should note that price remains a significant factor. The reforms do not eliminate price competition; they dilute its dominance. Foreign pharma companies must still offer price reductions, but the required discount is shallower — 25-30% under the new framework versus 40-45% under pure VBP — making margin preservation more achievable for patented and niche drugs.

Timeline: From VBP Squeeze to Policy Recalibration

Understanding the sequence of VBP reforms helps frame the current opportunity. China’s National Healthcare Security Administration (NHSA: 国家医疗保障局, guójiā yīliáo bǎozhàng jú) launched centralized drug procurement in pilot cities in 2018 with a “winner-take-most” model: the lowest bidding price won exclusive or near-exclusive hospital volume. By 2023, nine national VBP rounds had covered 374 drugs, achieving average price reductions of 53% and cumulative savings of approximately RMB 250 billion for the public medical insurance fund.

Foreign pharma companies responded by withdrawing drugs from VBP rounds rather than accepting unsustainable prices. In 2023, 34% of eligible foreign-brand drugs were voluntarily withdrawn from VBP bidding — up from 18% in 2020. This created a policy tension: NHSA achieved cost savings, but hospitals lost access to certain high-quality foreign drugs, and patients with ability to pay turned to out-of-hospital channels, reducing transparency in drug pricing and prescribing.

In response, NHSA began piloting the multi-dimensional tender framework in four provinces — Zhejiang, Jiangsu, Guangdong, and Shandong — in mid-2024. Early results showed improved foreign-participation rates (62% of eligible foreign drugs bid, versus 44% in pure VBP rounds) and narrower price differentials between domestic and foreign drugs within the same therapeutic class. Based on these pilots, NHSA mandated the new framework across all 23 provinces effective January 2025, with remaining provinces required to adopt by June 2025.

The 2024 NHSA guidance document also introduced a “quality trust list” (质量信任清单, zhìliàng xìnrèn qīngdān) — a pre-approved roster of 142 foreign and domestic drugs exempted from certain price-competition elements based on their proven safety records. Inclusion on this list provides a significant procedural advantage, as listed drugs automatically receive higher quality scores in tender evaluations.

Provincial Adoption and Market Impact Data

The pace of adoption varies across provinces, creating a fragmented early-stage environment that requires careful market-by-market analysis. Below is a representative breakdown of provincial tender framework adoption and foreign-pharma win rates in the first three months of 2025.

Several observations emerge from the provincial data. First, the full new framework provinces — where quality weight reaches 45-50% — show markedly higher foreign pharma win rates (27-33%) compared to hybrid or traditional VBP provinces (10-21%). Second, inclusion on the Quality Trust List correlates with win rates: provinces with more trust-listed drugs available for tender show higher foreign win rates, suggesting that early listing efforts yield direct market-access dividends. Third, the provincial variation means that a one-size-fits-all market access strategy will underperform; companies must tailor tender preparation by province.

The financial impact is measurable. Based on contract values for drugs bid in pilot provinces, the average revenue per successful foreign tender under the new framework is RMB 4.7 million per hospital per year — compared to RMB 2.1 million under pure VBP — primarily because shallower price discounts preserve margin and because multi-hospital contract bundles allow volume aggregation without monopolistic single-winner constraints.

Strategic Planning: Key Actions for Foreign Pharma Executives

The reformed tender system rewards preparation and data investment. Foreign pharma companies that proactively generate Chinese clinical real-world evidence, invest in local GMP certification maintenance, and apply for Quality Trust List inclusion will have structural advantages in tender evaluations. Companies that continue to rely on global pricing models and minimal local data generation will face persistent disadvantages — though less severe than under pure VBP.

The timeline for action is compressed. Provinces not yet on the full new framework must adopt by June 2025, meaning that tender submissions for H2 2025 cycles are already being prepared. Executives should also prepare for a second wave of reforms expected in 2026, when NHSA plans to introduce a “dynamic pricing adjustment” mechanism that links post-tender pricing to ongoing domestic R&D investment by winning bidders.

Two emerging opportunities warrant close attention. First, the new framework allows “dual-track bidding” for innovative drugs — companies can simultaneously bid in the standard tender channel and a new “innovation channel” that evaluates drugs primarily on clinical outcomes rather than price. Second, NHSA is piloting a “mutual recognition” system across provinces for tender awards, meaning a win in Zhejiang could eventually streamline approval in Fujian or Anhui, reducing the administrative burden of multi-province market access.

NEXT STEPS

1. Complete a province-by-province tender framework audit. Map your drug portfolio against the adoption status and scoring criteria in each of the 23 reformed provinces. Read our China Pharma Tender Guide 2025 for detailed provincial profiles and scoring calculators.
2. Apply for Quality Trust List inclusion before the June 2025 deadline. Identify all qualifying drugs and prepare safety-data submissions. Our step-by-step application checklist covers documentation requirements and translation needs.
3. Evaluate dual-track bidding eligibility for innovative drugs. For drugs with differentiated clinical profiles, the innovation channel offers a path to tender awards with minimal price reduction. See our case studies on dual-track bidding wins for three foreign pharma companies in the pilot provinces.

— China Gateway 360 —
Remote China market entry support, built around execution.